This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

5 Apr 2012

AMRI Signs License Agreement with Bessor Pharma

The two firms have entered a license agreement for the development of AMRI’s novel tubulin inhibitor compound for the treatment of cancer.

AMRI has signed an exclusive option to enter a license agreement with Bessor Pharma, LLC for the development of ALB 109564(a), AMRI’s novel tubulin inhibitor compound in Phase I trials for the treatment of cancer.


The option period is approximately eight months.


According to the deal, AMRI will receive an undisclosed option fee and reimbursement for certain costs associated with the intellectual property related to ALB 109564(a).


Bessor will conduct fund raising and coordinate a technology transfer and advanced development plan with AMRI. Upon exercising the option, Bessor will receive an exclusive license to the compound and will be responsibl

Related News